哮喘联盟

   摘要
   目的：总结利多卡因雾化治疗顽固性咳嗽和哮喘的有效性和安全性证据。
   数据来源：检索Pubmed（截至2012年11月）、国际药物学摘要数据库（1970年-2012年12月）和Cochrane图书馆（截至2012年），检索词为雾化、注射、吸入、咳嗽、哮喘和利多卡因。限于人体研究，英文语种。相关文献的参考文献一并阅览。
   文献纳入和数据提取：复习所有来源文献：纳入17项研究。7项研究（6项描述性研究，1项临床研究）显示利多卡因10-400mg雾化治疗对顽固性咳嗽有效。5项临床试验的结果相反。
   结果：虽然利多卡因雾化治疗不是顽固性咳嗽和哮喘的一线治疗，但当患者对其他药物不能耐受或无效之时，也不失为另一种选择。适当监测有助于确保患者安全。
 

                                                                    （苏楠 审校）
Ann Pharmacother. 2013 Apr 2. [Epub ahead of print]


 

Evidence for Therapeutic Uses of Nebulized Lidocaine in the Treatment of Intractable Cough and Asthma (April).

Slaton RM, Thomas RH, Mbathi JW.

Abstract
OBJECTIVE: To summarize the efficacy and safety data for use of nebulized lidocaine in intractable cough and asthma.
DATA SOURCES: A literature search was conducted using PubMed (through November 2012), International Pharmaceutical Abstracts (1970-December 2012), and Cochrane Library (up to 2012) with the search terms nebulization, nebulized or nebulised; administration, inhalation; cough; asthma; and lidocaine. Results were limited to human studies published in the English language. Referenced citations from relevant publications were also reviewed.
STUDY SELECTION AND DATA EXTRACTION: All articles identified from the DATA SOURCES: Seventeen studies were identified for review. Seven studies (6 descriptive studies and 1 clinical trial) evaluating the use of nebulized lidocaine in intractable cough reported efficacy in doses ranging from 10 mg to 400 mg. Five clinical trials in asthma showed conflicting .
RESULTS: Although nebulized lidocaine is not first-line therapy in intractable cough and asthma, it may provide an alternative treatment option in patients who cannot tolerate or are unresponsive to other treatments. Appropriate monitoring precautions should be used to ensure patient safet

Ann Pharmacother. 2013 Apr 2. [Epub ahead of print]